<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-GIJROJIJ</identifier><date>2019</date><creator>Matičič, Mojca</creator><relation>documents/doc/G/URN_NBN_SI_doc-GIJROJIJ_001.pdf</relation><relation>documents/doc/G/URN_NBN_SI_doc-GIJROJIJ_001.txt</relation><format format_type="issue">4</format><format format_type="volume">70</format><format format_type="type">article</format><format format_type="extent">str. 263-271</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">6609580</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-GIJROJIJ</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">hepatitis B</subject><subject language_type_id="slv">hepatitis C</subject><subject language_type_id="slv">na virus neposredno delujoče učinkovine</subject><subject language_type_id="slv">nukleotidni analogi</subject><subject language_type_id="slv">nukleozidni analogi</subject><subject language_type_id="slv">Slovenija</subject><title>Viral hepatitis</title><title>Virusni hepatitis</title></Record>